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In The Lancet Oncology, David Dearnley and 
colleagues1 report the long-term outcomes of the 
Medical Research Council (MRC) RT01 study—a 
randomised study of 64 Gy versus 74 Gy of conformal 
radiotherapy given with 3–6 months of neoadjuvant 
or concomitant androgen deprivation therapy (ADT). 
The authors are to be commended for completing 
and successfully managing this high quality trial 
over the past 20 years. As they rightly point out, this 
is one of six randomised trials that have examined 
the possible beneﬁ ts of dose escalation for external 
beam radiotherapy. In sum, an additional week of 
radiotherapy improves biochemical control by about 
18%.2 In this trial with 843 participants, the 10-year 
absolute diﬀ erence in biochemical progression-free 
survival was 12% (43% [95% CI 38–48] in the standard-
dose group vs 55% [50–61]; hazard ratio [HR] 0·69 
[95% CI 0·56–0·84]; p<0·0001) with no signiﬁ cant 
diﬀ erence in overall survival (71% [95% CI 66–75] in 
both groups; HR 0·99 [95% CI 0·77–1·28]; p=0·96).
Although overall survival is the gold-standard 
outcome to improve, it is exceptionally diﬃ  cult to 
show in localised disease diagnosed in a screen-
detected era when median overall survival approaches 
20 years. This diﬃ  culty is particularly evident when 
technological advances introduce supposedly better 
techniques every 2–5 years. Notably, the SWOG 8794 
study3 did not show an overall survival advantage 
when it reported its 10·6 year median follow-up 
results, despite having a high-risk postoperative 
population, and doing the trial early in the prostate-
speciﬁ c antigen (PSA) screening era. Although PSA 
recurrence is not a perfect surrogate for overall 
survival, clinical experience suggests that higher PSA 
control means that more patients feel good about 
their disease status, and are free of next-line treatment 
interventions with their attendant side-eﬀ ects and 
costs.
As the MRC RT01 study constitutes another piece 
of level 1 evidence, it is likely that dose-escalated 
radiotherapy with short-term ADT (at least compared 
with lower dose radiotherapy) will be listed as one 
of the options that should be oﬀ ered to men with 
localised prostate cancer when guidelines about 
management of localised prostate cancer are updated. 
We can add this to the list of recommendations in 
localised prostate cancer: long-term versus short-
term or no ADT for high-risk disease; radiotherapy 
plus ADT versus radiotherapy or ADT alone for 
high-risk disease; and adjuvant postoperative 
radiotherapy versus delayed or no postoperative 
radiotherapy for margin-positive or extracapsular 
disease. The problem is that much of what clinicians 
can oﬀ er is not based on level 1 evidence, despite 
many attempts to design appropriate trials—eg, 
early detection and screening; active surveillance; 
radical prostatectomy (in screened populations); 
robotic-assisted laparoscopic prostatectomy (in any 
population); low dose rate (LDR) brachytherapy; 
high dose rate (HDR) brachytherapy (compared with 
dose-escalated radiotherapy); intensity modulated 
radiotherapy; stereotactic ablative radiotherapy; 
cryotherapy; high intensity focused ultra sound; and 
focal ablative therapy. Each of these interventions will 
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probably have suﬃ  cient evidence to warrant possible 
recommendation in a guideline. 
Although the purists will say that randomised 
trials are needed to inform every decision, the 
pragmatist knows that there are limits to this 
statement. First, there are limitations (eg, of funds, 
trial organisations, and personnel) to designing, 
doing, and analysing these trials. Second, and 
arguably more importantly, there has to be a balance 
of interests to do a randomised trial—the patient and 
supervising physician have to be uncertain as to the 
best treatment, unbiased (particularly ﬁ nancially) 
about which treatment might be better, and for the 
patient, be willing to enter into the study and subject 
themselves to random allocation of treatment. 
Random treatment allocation, although statistically 
the best way to balance for known and unknown 
prognostic and predictive factors, contradicts 
the patient empowerment movement. Third, are 
clinicians willing to stop innovating while they wait 
20 years to design, enrol, and mature the results of 
each randomised controlled trial?
The debate over LDR brachytherapy versus dose-
escalated radiotherapy illustrates these points. 
In the MRC RT01 study, 46% of patients had 
biochemical failure by 10 years. Long-term results 
for LDR have shown 10-year failure ranging from 
6% (LDR monotherapy for low and intermediate 
risk disease, N=1006)4 to 10% (LDR boost for high-
risk disease, N=473).5 With the same patient risk 
distribution as RT01, the expected occurrence of overall 
biochemical failure would be 7·7% with LDR. Since LDR 
is cheaper (at least in Canada), more convenient for 
patients, more eﬃ  cient for the health-care system, and 
has equivalent or better quality of life,6 is it ethical to 
do a randomised trial of these two options?
We need more studies like the one reported by 
Dearnley and colleagues. However, for the sake 
of global health-care systems and economies, we 
also need to stop oﬀ ering ineﬀ ective and resource-
intensive treatments. Collectively, our greatest step 
forward might be to identify for each patient cohort 
the treatments that produce the highest incremental 
cost eﬀ ectiveness ratios, and fund those. All other 
treatments would need to prove (through randomised 
trials) that they are of equal or better value than those 
to be publicly funded.
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Oestrogen suppression using aromatase inhibitors is the 
cornerstone of adjuvant treatment for postmenopausal 
women with hormone receptor-positive early breast 
cancer.1 Both non-steroidal (anastrozole and letrozole) 
and steroidal (exemestane) aromatase inhibitors 
are more eﬃ  cacious than is tamoxifen for reduction 
of recurrence of breast cancer.2–4 The investigators 
of MA.27—in which exemestane was compared 
with anastrozole—reported no diﬀ erence for breast 
cancer-related outcomes between the two drugs.5 
Generic versions of all three aromatase inhibitors are 
available and are used interchangeably for adjuvant 
treatment of hormone-dependent early breast cancer 
in postmenopausal women.
